Evidence map›Paper›PMID 33881557›Full record

ArticleWorld journal of urology2021

Triggers and oncologic outcome of salvage radical prostatectomy, salvage radiotherapy and active surveillance after focal therapy of prostate cancer.

Jost von Hardenberg, Hannes Cash, Daniel Koch, Angelika Borkowetz, Johannes Bruendl, Sami-Ramzi Leyh-Bannurah, Timur H Kuru, Karl-Friedrich Kowalewski, Daniel Schindele, Katharina S Mala and 4 more

Open access · hybridAbstract read
In one paragraph

Article in World journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 1 country.

Jost von HardenbergDepartment of Urology and Urosurgery, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. jost.vonhardenberg@medma.uni-heidelberg.de.ORCID http://orcid.org/0000-0002-0728-681X
Hannes CashDepartment of Urology, Charité University Medicine Berlin, Berlin, Germany.
Daniel KochDepartment of Urology, Fuerth Hospital, Fuerth, Germany.
Angelika BorkowetzDepartment of Urology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Johannes BruendlDepartment of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
Sami-Ramzi Leyh-BannurahDepartment of Urology, Pediatric Urology and Urologic Oncology, Prostate Center Northwest, St. Antonius-Hospital, Gronau, Germany.
Timur H KuruDepartment of Urology, University Hospital Cologne, University of Cologne, Cologne, Germany.
Karl-Friedrich KowalewskiDepartment of Urology and Urosurgery, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Daniel SchindeleClinic of Urology, Urooncology, Robotic-Assisted and Focal Therapy, Medical Faculty and University Clinics of Magdeburg, Magdeburg, Germany.
Katharina S MalaDepartment of Urology, Charité University Medicine Berlin, Berlin, Germany.
Niklas WesthoffDepartment of Urology and Urosurgery, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Andreas BlanaDepartment of Urology, Fuerth Hospital, Fuerth, Germany.
Martin SchostakClinic of Urology, Urooncology, Robotic-Assisted and Focal Therapy, Medical Faculty and University Clinics of Magdeburg, Magdeburg, Germany.
Working Group of Focal and Microtherapy of the German Society of Urology (DGU)
Heidelberg University · DEKlinikum Fulda · DEUniversity Hospital Magdeburg · DEAturo · DECharité - Universitätsmedizin Berlin · DESt.-Antonius-Hospital Gronau · DEUniversity Hospital Carl Gustav Carus · DEUniversity of Cologne · DEUniversity of Regensburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDue to the tissue preserving approach of focal therapy (FT), local cancer relapse can occur. Uncertainty exists regarding triggers and outcome of salvage strategies.

methodsPatients with biopsy-proven prostate cancer (PCa) after FT for localized PCa from 2011 to 2020 at eight tertiary referral hospitals in Germany that underwent salvage radical prostatectomy (S-RP), salvage radiotherapy (S-RT) or active surveillance (AS) were reported. Prostate specific antigen (PSA) changes, suspicious lesions on mpMRI and histopathological findings on biopsy were analyzed. A multivariable regression model was created for adverse pathological findings (APF) at S-RP specimen. Kaplan-Meier curves were generated to determine oncological outcomes.

resultsA total of 90 men were included. Cancer relapse after FT was detected at a median of 12 months (IQR 9-16). Of 50 men initially under AS 13 received S-RP or S-RT. In total, 44 men underwent S-RP and 13 S-RT. At cancer relapse 17 men (38.6%) in the S-RP group [S-RT n = 4 (30.8%); AS n = 3 (6%)] had ISUP > 2. APF (pT ≥ 3, ISUP ≥ 3, pN + or R1) were observed in 23 men (52.3%). A higher ISUP on biopsy was associated with APF [p = 0.006 (HR 2.32, 97.5% CI 1.35-4.59)] on univariable analysis. Progression-free survival was 80.4% after S-RP and 100% after S-RT at 3 years. Secondary therapy-free survival was 41.7% at 3 years in men undergoing AS. Metastasis-free survival was 80% at 5 years for the whole cohort.

conclusionWith early detection of cancer relapse after FT S-RP and S-RT provide sufficient oncologic control at short to intermediate follow-up. After AS, a high secondary-therapy rate was observed.

Indexed as

ProstatectomyRadiotherapySalvage TherapyWatchful WaitingAgedHigh-Intensity Focused Ultrasound AblationHumansKaplan-Meier EstimateMaleMiddle AgedMultiparametric Magnetic Resonance ImagingMultivariate AnalysisNeoplasm Recurrence, LocalProgression-Free SurvivalProstate-Specific AntigenProstatic NeoplasmsProstate-Specific AntigenFocal therapyHemi-ablationHigh-intensity focused ultrasoundMultiparametric magnetic resonance imagingPartial gland ablationProstate neoplasmsSalvage therapy

Identifiers

PMID33881557
PMCPMC8519844
OpenAlexW3152822233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.